Metabolomic Profiles Associated With Blood Pressure Reduction in Response to the DASH and DASH-Sodium Dietary Interventions.
Metabolomic Profiles Associated With Blood Pressure Reduction in Response to the DASH and DASH-Sodium Dietary Interventions.
复制标题
DOI：
10.1161/hypertensionaha.123.20901
复制
发表时间：
2023-07
期刊：
影响因子：
8.3
通讯作者：
Rebholz, Casey M.
中科院分区：
文献类型：
--
作者：
Kim, Hyunju;Appel, Lawrence J.;Lichtenstein, Alice H.;Wong, Kari E.;Chatterjee, Nilanjan;Rhee, Eugene P.;Rebholz, Casey M.
关键词：
在DASH和DASH-Sodium试验中，DASH（阻止高血压的饮食方法）饮食降低了血压（BP），但其潜在机制尚不清楚。我们在2项随机对照喂养研究（DASH和DASH-钠试验）中确定了与饮食干预（DASH与对照组）诱导的收缩压或舒张压（DBP）变化相关的代谢物。在饮食干预结束时收集的血清和尿液样本中进行代谢组学分析：DASH（n=219）和DASH-钠（n=395）。使用多变量线性回归模型，研究代谢物与收缩压和舒张压变化之间的相关性。对饮食干预和代谢物之间的相互作用进行了以下比较：（1）DASH试验中的DASH与对照饮食（血清），（2）DASH-钠试验中的DASH高钠与对照高钠饮食（尿液），以及（3）DASH-钠试验中的DASH低钠与对照高钠饮食（尿液）。在代谢物与收缩压或DBP之间确定了65种显著的相互作用（DASH试验[血清]，12; DASH高钠[尿液]，35; DASH低钠[尿液]，18）。在DASH试验中，血清色氨酸甜菜碱与食用DASH饮食而不是对照饮食的参与者的DBP降低相关（P相互作用，0.023）。在DASH-钠试验中，尿中N-甲基谷氨酸盐和脯氨酸衍生物（例如，水苏碱、3-羟基水苏碱、N-甲基脯氨酸和N-甲基羟脯氨酸）的水平与摄入DASH饮食的参与者的收缩压或DBP降低相关，但与对照饮食无关（P相互作用，所有试验<0.05）。我们确定了与饮食干预降低血压相关的代谢物。URL：https：//www.clinicaltrials.gov/ct2/show/NCT03403166;唯一标识符：NCT 03403166（DASH试验）。URL：https：//www.clinicaltrials.gov/ct2/show/NCT 00000608;唯一标识符：NCT 00000608（DASH-钠试验）。
The DASH (Dietary Approaches to Stop Hypertension) diets reduced blood pressure (BP) in the DASH and DASH-Sodium trials, but the underlying mechanisms are unclear. We identified metabolites associated with systolic BP or diastolic BP (DBP) changes induced by dietary interventions (DASH versus control arms) in 2 randomized controlled feeding studies—the DASH and DASH-Sodium trials. Metabolomic profiling was conducted in serum and urine samples collected at the end of diet interventions: DASH (n=219) and DASH-Sodium (n=395). Using multivariable linear regression models, associations were examined between metabolites and change in systolic BP and DBP. Tested for interactions between diet interventions and metabolites were the following comparisons: (1) DASH versus control diets in the DASH trial (serum), (2) DASH high-sodium versus control high-sodium diets in the DASH-Sodium trial (urine), and (3) DASH low-sodium versus control high-sodium diets in the DASH-Sodium trial (urine). Sixty-five significant interactions were identified (DASH trial [serum], 12; DASH high sodium [urine], 35; DASH low sodium [urine], 18) between metabolites and systolic BP or DBP. In the DASH trial, serum tryptophan betaine was associated with reductions in DBP in participants consuming the DASH diets but not control diets (P interaction, 0.023). In the DASH-Sodium trial, urine levels of N-methylglutamate and proline derivatives (eg, stachydrine, 3-hydroxystachydrine, N-methylproline, and N-methylhydroxyproline) were associated with reductions in systolic BP or DBP in participants consuming the DASH diets but not control diets (P interaction, <0.05 for all tests). We identified metabolites that were associated with BP lowering in response to dietary interventions. URL: https://www.clinicaltrials.gov/ct2/show/NCT03403166; Unique identifier: NCT03403166 (DASH trial). URL: https://www.clinicaltrials.gov/ct2/show/NCT00000608; Unique identifier: NCT00000608 (DASH-Sodium trial).
影响因子：
5
作者：
Zhu, Yinjie;Frank, Jan;Riphagen, Ineke J.;Minovic, Isidor;Vos, Michel J.;Eggersdorfer, Manfred L.;Navis, Gerjan J.;Bakker, Stephan J. L.
通讯作者：
Bakker, Stephan J. L.